Press
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
15 January, 2024
https://www.the-scientist.com/news-opinion/more-cancer-mutations--better-immunotherapy-outcomes-65323
Δ
Company
Resources
Research
Diagnostics
Contact